David E. Adelberg

1.3k total citations
37 papers, 542 citations indexed

About

David E. Adelberg is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, David E. Adelberg has authored 37 papers receiving a total of 542 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 7 papers in Surgery. Recurrent topics in David E. Adelberg's work include Colorectal Cancer Treatments and Studies (15 papers), Gastric Cancer Management and Outcomes (13 papers) and Prostate Cancer Treatment and Research (9 papers). David E. Adelberg is often cited by papers focused on Colorectal Cancer Treatments and Studies (15 papers), Gastric Cancer Management and Outcomes (13 papers) and Prostate Cancer Treatment and Research (9 papers). David E. Adelberg collaborates with scholars based in United States, South Korea and Japan. David E. Adelberg's co-authors include Eric Van Cutsem, Charles S. Fuchs, Yung‐Jue Bang, Josep Tabernero, Kohei Shitara, Vivian E. Strong, Takaki Yoshikawa, David H. Ilson, Atsushi Ohtsu and Nancy R. Webb and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Biochemical and Biophysical Research Communications.

In The Last Decade

David E. Adelberg

33 papers receiving 534 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David E. Adelberg United States 13 317 305 170 106 85 37 542
Daniel Virgil Thomas Catenacci United States 11 365 1.2× 271 0.9× 167 1.0× 74 0.7× 112 1.3× 19 524
Fernando Rivera Spain 13 331 1.0× 372 1.2× 174 1.0× 92 0.9× 157 1.8× 27 612
Takashi Ichimura Japan 12 361 1.1× 274 0.9× 143 0.8× 56 0.5× 96 1.1× 52 579
Rita P. Dalal United States 10 415 1.3× 311 1.0× 144 0.8× 103 1.0× 92 1.1× 21 622
Hong Jo Choi South Korea 12 276 0.9× 174 0.6× 177 1.0× 52 0.5× 148 1.7× 25 546
Fabiola Lorena Rojas Llimpe Italy 10 500 1.6× 498 1.6× 217 1.3× 135 1.3× 117 1.4× 32 791
Laura Giannetta Italy 9 369 1.2× 432 1.4× 151 0.9× 95 0.9× 83 1.0× 21 587
Katsuhiko Ehi Japan 14 172 0.5× 366 1.2× 249 1.5× 184 1.7× 46 0.5× 25 574
Anghel Adrian Udrea United States 8 261 0.8× 227 0.7× 96 0.6× 58 0.5× 96 1.1× 15 392
B-Y. Ryoo South Korea 9 313 1.0× 332 1.1× 166 1.0× 115 1.1× 76 0.9× 36 581

Countries citing papers authored by David E. Adelberg

Since Specialization
Citations

This map shows the geographic impact of David E. Adelberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David E. Adelberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David E. Adelberg more than expected).

Fields of papers citing papers by David E. Adelberg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David E. Adelberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David E. Adelberg. The network helps show where David E. Adelberg may publish in the future.

Co-authorship network of co-authors of David E. Adelberg

This figure shows the co-authorship network connecting the top 25 collaborators of David E. Adelberg. A scholar is included among the top collaborators of David E. Adelberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David E. Adelberg. David E. Adelberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Segal, Neil H., Maria Passhak, Eugen Kubala, et al.. (2025). Co-formulated favezelimab plus pembrolizumab versus standard-of-care in previously treated, PD-L1-positive metastatic colorectal cancer: The phase 3, randomized KEYFORM-007 study.. Journal of Clinical Oncology. 43(4_suppl). 2 indexed citations
3.
4.
Takashima, Atsuo, Pilar García‐Alfonso, Ali Ayberk Beşen, et al.. (2024). Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study. European Journal of Cancer. 205. 114036–114036. 7 indexed citations
5.
Kim, Richard D., Mustapha Tehfé, Petr Kavan, et al.. (2024). Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D. Clinical Colorectal Cancer. 23(2). 118–127.e6. 8 indexed citations
6.
Chen, Eric X., Petr Kavan, Mustapha Tehfé, et al.. (2024). Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E. Clinical Colorectal Cancer. 23(2). 183–193. 2 indexed citations
7.
André, Thierry, Tae Won Kim, Benny Vittrup Jensen, et al.. (2024). Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study. Annals of Oncology. 36(3). 277–284. 27 indexed citations
8.
9.
Kawazoe, Akihito, Rui‐Hua Xu, Maria Passhak, et al.. (2023). LBA-5 Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer (mCRC): the phase 3 LEAP-017 study. Annals of Oncology. 34. S179–S179. 16 indexed citations
10.
Bekaii‐Saab, Tanios, Eric Van Cutsem, Josep Tabernero, et al.. (2023). MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer.. Journal of Clinical Oncology. 41(16_suppl). TPS3631–TPS3631. 2 indexed citations
11.
Shitara, Kohei, Mustafa Özgüroğlu, Maria Di Bartolomeo, et al.. (2021). Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma. Annals of Oncology. 32(9). 1127–1136. 42 indexed citations
12.
Yoshino, Takayuki, Roxana Fu, Natalyn Hawk, et al.. (2021). 506TiP Pembrolizumab plus lenvatinib versus standard of care for previously treated metastatic colorectal cancer (mCRC): Phase III LEAP-017 study. Annals of Oncology. 32. S580–S580. 4 indexed citations
13.
14.
15.
Fuchs, Charles S., Mustafa Özgüroğlu, Yung‐Jue Bang, et al.. (2020). The association of molecular biomarkers with efficacy of pembrolizumab versus paclitaxel in patients with gastric cancer (GC) from KEYNOTE-061.. Journal of Clinical Oncology. 38(15_suppl). 4512–4512. 22 indexed citations
16.
Bang, Yung‐Jue, Eric Van Cutsem, Charles S. Fuchs, et al.. (2019). KEYNOTE-585: Phase III Study of Perioperative Chemotherapy with or Without Pembrolizumab for Gastric Cancer. Future Oncology. 15(9). 943–952. 134 indexed citations
17.
Karzai, Fatima, Andrea B. Apolo, Liang Cao, et al.. (2014). A phase I study of TRC 105 anti‐endoglin ( CD 105) antibody in metastatic castration‐resistant prostate cancer. British Journal of Urology. 116(4). 546–555. 54 indexed citations
18.
Dahut, William L., Ravi A. Madan, Joyson Karakunnel, et al.. (2013). Phase II clinical trial of cediranib in patients with metastatic castration‐resistant prostate cancer. British Journal of Urology. 111(8). 1269–1280. 36 indexed citations
19.
English, Bevin C., et al.. (2010). A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. SHILAP Revista de lepidopterología. 5 indexed citations
20.
Adelberg, David E. & Michael R. Bishop. (2009). Emergencies Related to Cancer Chemotherapy and Hematopoietic Stem Cell Transplantation. Emergency Medicine Clinics of North America. 27(2). 311–331. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel Virgil Thomas Catenacci Breakdown of academic impact, for papers by Fernando Rivera Breakdown of academic impact, for papers by Takashi Ichimura Breakdown of academic impact, for papers by Rita P. Dalal Breakdown of academic impact, for papers by Hong Jo Choi Breakdown of academic impact, for papers by Fabiola Lorena Rojas Llimpe Breakdown of academic impact, for papers by Laura Giannetta Breakdown of academic impact, for papers by Katsuhiko Ehi Breakdown of academic impact, for papers by Anghel Adrian Udrea Breakdown of academic impact, for papers by B-Y. Ryoo
Rankless by CCL
2026